Origin of MM cells

Chair(s)

• 

  Nikhil Munshi, MD

  Kraft Family Chair, Director of Basic and Correlative Science, Professor of Medicine, Harvard Medical School
  Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts, United States

Co-Chair(s)

• 

  Faith Davies, MD (she/her/hers)

  Professor of Medicine, Director of the Center for Blood Cancers Director of the Clinical Myeloma Pro
  Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA, United States

Presentations:

• 10:15 AM – 10:25 AM EEST

  Charting the genetic evolution in myeloma cell
  

  Speaker: Faith E. Davies, MD (she/her/hers) – Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
• 10:25 AM – 10:35 AM EEST

  Novel in vivo models of myeloma origin
  

  Speaker: Karin Vanderkerken, PhD (she/her/hers) – Vrije Universiteit Brusssels
• 10:35 AM – 10:45 AM EEST

  Failure of immune surveillance and disease evolution
  

  Speaker: Madhav V. Dhodapkar, MD, MBBS (he/him/his) – Winship Cancer Institute, Emory University, Atlanta, GA, USA
• 10:45 AM – 10:55 AM EEST

  Is there a role for screening in monoclonal gammopathies?
  

  Speaker: Sigurdur Y. Kristinsson, MD, PhD – University of Iceland
• 10:55 AM – 11:05 AM EEST

  OA-17: Tracking the earliest genomic events in multiple myeloma life-history
  

  Speaker: Anthony Cirrincione, PhD – Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami
• 11:05 AM – 11:15 AM EEST

  OA-33: Aberrant B cell differentiation induce plasma cell malignancy
  

  Speaker: Wen Zhou, PhD – Cancer Research Institute, Xiangya School of Medicine, Central South University
• 11:15 AM – 11:25 AM EEST

  OA-25: MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells
  

  Speaker: Rodger E. Tiedemann, MD, PhD (he/him/his) – Princess Margaret Cancer Centre
• 11:30 AM – 11:45 AM EEST

  Discuss abstracts in context
  

  Speaker: Leif Bergsagel, MD – Mayo Clinic Arizona
• 11:45 AM – 12:15 PM EEST

  Round table discussion
  

  Panelist: Rafael Fonseca, MD – Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA

  Panelist: Andrew Spencer, MBBS FRACP, FRCPA, DM – Alfred Health-Monash University

  Panelist: Rodger E. Tiedemann, MD, PhD (he/him/his) – Princess Margaret Cancer Centre

  Panelist: Marta Chesi, PhD (she/her/hers) – Mayo Clinic Arizona